Valuation: ABIONYX Pharma SA

Market Cap 65.12M 72.88M 60.75M 55.18M 104M 7.05B 105M 730M 285M 3.59B 274M 268M 11.53B P/E 2026 *
-4.61x
P/E 2027 * -4.65x
Enterprise Value 53.92M 60.34M 50.3M 45.69M 86.05M 5.84B 86.7M 604M 236M 2.97B 227M 222M 9.54B EV / Sales 2026 *
12x
EV / Sales 2027 * 5.55x
Free-Float
72.26%
Yield 2026 *
-
Yield 2027 * -
1 day-1.44%
1 week-13.19%
Current month-13.19%
1 month-18.03%
3 months-21.30%
6 months-56.96%
Current year-56.27%
1 week 1.5
Extreme 1.5
1.74
1 month 1.5
Extreme 1.5
1.95
Current year 1.5
Extreme 1.5
4.08
1 year 1.5
Extreme 1.5
4.26
3 years 0.95
Extreme 0.947
4.37
5 years 0.95
Extreme 0.947
4.37
10 years 0.18
Extreme 0.1766
4.37
Manager TitleAgeSince
Chief Executive Officer 49 2019-09-05
Director of Finance/CFO - -
Chief Operating Officer - 2005-12-31
Director TitleAgeSince
Director/Board Member 49 2019-09-05
Director/Board Member 52 2010-07-19
Director/Board Member 76 2015-02-05
Change 5-day change 1-year change 3-year change Capi.($)
-1.44%-13.19% - - 72.88M
+4.16%+4.16%+49.37%+94.17% 74.68B
-15.41%-15.73%+3.20%+51.86% 58.7B
-1.39%+1.50%+4.44%+32.63% 48.36B
+0.50%-2.14%+331.33%+702.20% 43.05B
-0.72%-3.99%+28.50%+29.94% 42.48B
+0.34%-0.52%+6.56%+109.35% 41.39B
-0.11%+1.96%+9.19%+52.66% 31.29B
-0.50%-3.10%-10.19%-14.35% 23.93B
-3.32%-10.86%-37.32%+316.28% 22.22B
Average -1.79%-2.18%+42.79%+152.75% 42.9B
Weighted average by Cap. -1.93%-1.56%+49.34%+145.08%

Financials

2026 *2027 *
Net sales 4.51M 5.04M 4.2M 3.82M 7.19M 488M 7.25M 50.52M 19.74M 248M 18.93M 18.53M 798M 11.28M 12.62M 10.52M 9.56M 18M 1.22B 18.13M 126M 49.4M 621M 47.39M 46.36M 2B
Net income -14.48M -16.21M -13.51M -12.27M -23.12M -1.57B -23.29M -162M -63.44M -798M -60.86M -59.54M -2.56B -14.75M -16.51M -13.76M -12.5M -23.54M -1.6B -23.71M -165M -64.6M -812M -61.97M -60.63M -2.61B
Net Debt -11.2M -12.53M -10.45M -9.49M -17.88M -1.21B -18.01M -126M -49.06M -617M -47.06M -46.04M -1.98B -2.5M -2.8M -2.33M -2.12M -3.99M -271M -4.02M -28.03M -10.95M -138M -10.5M -10.28M -443M
Projected Income Statement - Annual - ABIONYX Pharma SA
Logo ABIONYX Pharma SA
ABIONYX Pharma SA is specialized in research & development into HDL therapies (High Density lipoproteins) intended for the treatment of cardiovascular and metabolic disorders. HDLs, also known as good cholesterol, are fat and protein complexes that contribute to the transportation of cholesterol from the body's tissues to the liver and are linked to a decrease in the risk of atherosclerosis and coronary diseases. At the end of 2025, the company boasted a portfolio of 3 products in clinical development.
Employees
49
Date Price Change Volume
26-10-08 €1.500 -1.83% 0
26-10-07 €1.528 -0.52% 0
26-10-06 €1.536 -3.03% 6,000
26-10-05 €1.584 -1.12% 0
26-10-02 €1.602 -4.87% 3,528
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - ABIONYX Pharma SA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.538EUR
Average target price
9.833EUR
Spread / Average Target
+539.36%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - ABIONYX Pharma SA